Patients’ characteristics classified by Severity of COVID-19 (n=147) |
Severity 5 (SYMP) (Patients died) (n = 26) |
Severity 4 (SYMP) (ICU + vent.) (n = 15) |
Severity 3 (SYMP) (ICU) (n = 21) |
Severity 2 (SYMP) (Inpatients, Reg. Adm.) (n = 64) |
Severity 1 (SYMP) (ED) (n = 12) |
Severity 0 (ASYMP) (n = 9) |
|
---|---|---|---|---|---|---|---|
Demographic features | Age median | 65 (39-90) | 52 (33-85) | 53 (26-86) | 57 (23-85) | 51 (27-91) | 27 (19-51) |
Gender (Male/Female) | 19/7 (73%/27%) | 9/6 (60%/40%) | 13/8 (62%/38%) | 37/27 (58%/42%) | 5/7 (42%/58%) | 5/4 (56%/44%) | |
Race (% White/non-White) | 6/20 (23%/77%) | 8/7 (53%/47%) | 13/8 (62%/38%) | 25/39 (39%/61%) | 7/5 (58%/42%) | 2/7 (29%/71%) | |
Class I & II HLA status | |||||||
HLA-A*0201+ | 13 (50%) | 8 (53%) | 12 (57%) | 24 (38%) | 7 (58%) | 7 (78%) | |
HLA-DRB1*01:01+ | 14 (54%) | 11 (73%) | 12 (57%) | 41 (64%) | 7 (58%) | 7 (78%) | |
Clinical parameters | |||||||
(4.8 days average for all 147 patients) | |||||||
Days between onset of symptoms and blood draw (mean) | 5.9 | 5.7 | 4.6 | 4.5 | 4.1 | - | |
Fever (>38°C) | 21 (81%) | 11 (73%) | 10 (48%) | 30 (47%) | 4 (33%) | 0 (0%) | |
Cough | 23 (88%) | 13 (87%) | 16 (76%) | 22 (34%) | 4 (33%) | 0 (0%) | |
Shortness of Breath/Dyspnea | 28 (100%) | 15 (100%) | 6 (29%) | 11 (17%) | 1 (8%) | 0 (0%) | |
Fatigue/Myalgia | 9 (35%) | 5 (33%) | 6 (29%) | 3 (5%) | 3 (25%) | 0 (0%) | |
Headache | 5 (19%) | 1 (%) | 4 (19%) | 12 (19%) | 4 (33%) | 0 (0%) | |
Nausea | 3 (12%) | 3 (20%) | 3 (14%) | 3 (5%) | 0 (0%) | 0 (0%) | |
Diarrhea | 7 (27%) | 2 (13%) | 2 (10%) | 8 (13%) | 0 (0%) | 0 (0%) | |
Anosmia/Ageusia | 6 (23%) | 4 (27%) | 6 (29%) | 17 (27%) | 1 (8%) | 0 (0%) | |
Sore Throat | 4 (15%) | 1 (7%) | 1 (5%) | 3 (5%) | 1 (8%) | 0 (0%) | |
ICU Admission | 26 (100%) | 15 (100%) | 21 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | |
Ventilator Support | 26 (100%) | 15 (100%) | 0 (0%) | 0 (0% | 0 (0%) | 0 (0%) | |
White Blood Cells – (count: 103 cells /μL of blood) (average) | 14.3 | 10.8 | 10.1 | 8.4 | 6.2 | 8.0 | |
Lymphocytes – (103 cells /μL of blood and %) (average) | 0.7 (6%) | 0.9 (10%) | 1.0 (13%) | 1.4 (16%) | 1.6 (27%) | 2.4 (29.3%) | |
Comorbidities | |||||||
Average number of all comorbidities | 3.5 | 2.9 | 2.8 | 1.9 | 1.6 | 0.7 | |
Diabetes | 14 (54%) | 9 (60%) | 13 (62%) | 29 (45%) | 4 (33%) | 0 (0%) | |
Hypertension (HTN) | 16 (62%) | 6 (40%) | 9 (43%) | 18 (28%) | 4 (33%) | 1 (11%) | |
Cardiovascular disease (CVD) | 17 (65%) | 6 (40%) | 6 (29%) | 13 (20%) | 3 (25%) | 0 (0%) | |
Coronary Artery disease (CAD) | 12 (46%) | 5 (33%) | 7 (33%) | 12 (19%) | 2 (17%) | 0 (0%) | |
Kidney diseases (CKD/ESRD) | 7 (27%) | 4 (27%) | 6 (29%) | 7 (11%) | 1 (8%) | 0 (0%) | |
Asthma/COPD | 9 (35%) | 1 (7%) | 3 (14%) | 12 (19%) | 0 (0%) | 1 (11%) | |
Obesity | 12 (46%) | 12 (80%) | 7 (33%) | 29 (45%) | 4 (33%) | 4 (44%) | |
Cancer | 4(15%) | 0(0%) | 2(10%) | 6(9%) | 1(8%) | 0 (0%) |